Track topics on Twitter Track topics that are important to you
John Burt, chief executive of Abzena plc (AIM:ABZA), tells Proactive's Andrew Scott the group expects turnover for the 12 months to the end of March to be in the order of £22mln, up 18% on the year before, with underlying earnings (EBITDA) in line with expectations.
There was a marked split between halves, with sales up 49% in the second six months compared with the first.
Abzena's targeting top-line growth in 2019 at a “slightly higher rate” than 2018, with the performance expected to be second-half weighted.NEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...